간질성 방광염(IC) : 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(2025-2035년)

Interstitial Cystitis (IC) Market Outlook

Thelansis's "Interstitial Cystitis (IC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Interstitial Cystitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Interstitial Cystitis (IC) Overview

Interstitial cystitis (IC), or bladder pain syndrome, is a chronic disorder causing recurrent pelvic pain, urgency, and frequency without infection, driven by urothelial dysfunction, hyperpermeability, and neurogenic sensitization. Pain characteristically worsens with bladder filling and is relieved by voiding. Diagnosis is clinical, requiring the exclusion of confusable conditions via cystoscopy and culture; a distinct Hunner lesion phenotype requires localized endoscopic identification. Rather than a rigid stepwise ladder, 2026 guidelines mandate a simultaneous, phenotype-directed multimodal strategy. Initial care combines trigger avoidance with pelvic floor physiotherapy. Oral amitriptyline provides systemic relief, while oral pentosan polysulfate is strictly restricted due to irreversible pigmentary maculopathy risks. Intravesical lidocaine or heparin instillations address mucosal symptoms, and Hunner lesions are treated with endoscopic fulguration. Refractory disease utilizes intradetrusor botulinum toxin or sacral neuromodulation.

Key Highlights

• In Germany, the prevalent population of Interstitial Cystitis (IC) is projected to increase from 831,982 in 2025 to 840,339 by 2035.
• Interstitial Cystitis is a chronic bladder disorder characterized by pelvic pain, urinary urgency, and increased urinary frequency, significantly impacting quality of life.
• The heterogeneous nature of the disease and lack of definitive diagnostic biomarkers continue to pose challenges for timely diagnosis and effective management.
• Despite the availability of multiple treatment approaches, substantial unmet need remains for therapies that provide durable symptom relief and address underlying disease mechanisms.

Market Overview

• The Italy Interstitial Cystitis market is projected to grow from $85M in 2025 to $155M by 2035.
• Market growth is driven by:
• Increasing disease awareness and improved diagnosis among patients with chronic bladder pain symptoms
• Ongoing development of novel therapies targeting pain, inflammation, and bladder dysfunction
• Future growth will depend on the availability of more effective treatments capable of delivering sustained symptom control and improving patient quality of life.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Ono Pharmaceutical Co., Ltd.
• Imbrium Therapeutics
• Vaneltix Pharma, Inc.
• AbbVie

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)